Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/01/24
End: 11/01/26
Due: 11/01/27
Phase: N/A
Priority: Normal
Start: 09/30/15
End: 05/01/20
Due: 05/01/21
Phase: N/A
Priority: Normal
Start: 06/26/18
End: 06/25/24
Due: 06/25/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | NCT06067776 | Jonathan Riess | user2@example.com | None | 2024-01-01 | 2026-11-01 | 2027-11-01 | - | - | 2025-07-14 |
| Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | NCT02364609 | Jonathan Riess | user2@example.com | None | 2015-09-30 | 2020-05-01 | 2021-05-01 | - | - | 2025-07-14 |
| Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations | NCT03299088 | Jonathan Riess | user2@example.com | None | 2018-06-26 | 2024-06-25 | 2025-06-25 | - | - | 2025-07-14 |